Mission Produce, Inc. (AVO) · Oct 8, 2026 · Guidance
Guidance reaffirmed — H2 FY2026 Adjusted EBITDA $84–88M; Q4 $52–55M
Mission Produce’s Investor Day reaffirms fiscal 2026 guidance and outlines a five-year growth plan, with Calavo synergies raised above $30 million.
Mission Produce is moving from a heavy investment-and-expansion phase into executing the Calavo integration and turning its avocado distribution network into higher-margin growth; its latest quarter already framed integration, synergies, and cash generation as the central business story.
The near-term outlook is unchanged, not upgraded. Management reaffirmed fiscal 2026 second-half Adjusted EBITDA of $84–88 million and fourth-quarter Adjusted EBITDA of $52–55 million. 〔0〕 That makes this confirmation rather than an earnings surprise: the filing gives investors no new operating forecast above the existing framework.
| Measure | Filing / updated target | Comparison or context |
|---|---|---|
| FY2026 second-half Adjusted EBITDA | $84–88M | Reaffirmed guidance |
| FY2026 Q4 Adjusted EBITDA | $52–55M | Reaffirmed guidance |
| Annualized Calavo synergies | More than $30M | Raised from at least $25M; full run-rate targeted within 18 months |
| Five-year organic sales growth | Mid-single digits | Company target |
| Five-year Adjusted EBITDA growth | High-single digits+ | Company target |
| Five-year margin expansion | ~300 bps | Company target |
| Free-cash-flow conversion | >90% | Target by 2027 |
| Net debt / Adjusted EBITDA | <1.5x | Target within two years |
| Share-repurchase authorization | $100M | 290,994 shares repurchased in Q4-to-date at $12.94 average |
The one tangible upgrade is the synergy target, but it is not entirely new. Mission raised the expected annualized Calavo benefit to more than $30 million from at least $25 million, a greater-than-20% increase. However, the company had already disclosed that increase in its fiscal third-quarter release, so Investor Day confirms execution progress rather than creating a fresh surprise. The filing says only a small contribution is expected in Q4 2026, with the full run-rate still dependent on completing network, systems, Mexico packing, and Prepared Foods integration. 〔1〕
The strategic plan is more ambitious than the near-term evidence. Mission targets $4 billion of sales and $450 million of Adjusted EBITDA by 2035, supported by mid-single-digit organic sales growth, high-single-digit-plus Adjusted EBITDA growth, roughly 300 basis points of margin expansion, and greater than 90% free-cash-flow conversion. These are explicitly ambitions rather than guidance, so they expand the long-term narrative but do not yet change the near-term financial bar.
Execution risk remains concentrated in integration and leverage. The company has completed early U.S. network actions, including pooling supply and closing Temecula, but major systems and remaining operations work continues through 2027. 〔2〕 The balance-sheet objective is also meaningful: management shows fiscal 2026E net leverage at 2.7x versus a target below 1.5x, making deleveraging and cash conversion central tests of whether the strategy becomes financially real.
Capital returns are supportive but discretionary. The $100 million authorization and current repurchases add flexibility, but management expressly describes buybacks as opportunistic rather than committed. That is a capital-allocation signal, not a new earnings driver.
Bottom line: Investor Day strengthens the Calavo integration story and raises the long-term synergy ceiling, but most of the substance was already known. The immediate business read is therefore confirmation with a modest strategic upgrade, not a step-change in near-term expectations.
Q4 fiscal 2026 results, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!